NeuroOne reports successful large-animal procedures using next-generation StereoCED platform

Reuters2026/08/27 13:05

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

NeuroOne completed three large-animal procedures using its next-generation StereoCED platform for robotic-assisted intracerebral drug delivery.
Two procedures achieved targeted drug delivery with simultaneous intracranial electrophysiological recording from the same brain regions.
Work supports a planned launch for human investigational clinical studies later this quarter.
StereoCED devices for animal use finished early, enabling earlier sales; related revenue is expected to be recognized in fiscal Q4 2026.
Devices for human investigational use remain on track for release by the end of fiscal Q4 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neuroone Medical Technologies Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-094174), on August 27, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

NeuroOne reports successful large-animal procedures using next-generation StereoCED platform

You may also like

Crypto prices